You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men and women age 18 and older with Urothelial Carcinoma (UCa) to check safety and tolerability of INO-5401 + INO-9012 delivered by intramuscular injection followed by electroporation (EP) with CELLECTRA 2000 device in combination with Atezolizumab. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women 18 years and older 
  • Pathologically confirmed advanced unresectable or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra) 
  • Detailed eligibility reviewed when you contact the study team 

Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.

This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery.

This research study is a Phase IIIb clinical trial. Phase IIIb clinical trials examine the safety and effectiveness of a drug or treatment, often comparing it to another known treatment. 

Key Inclusion / Exclusion Criteria:

Inclusion Criteria

  • Patients with a newly diagnosed, objectively confirmed: symptomatic or unsuspected, proximal lower-limb DVT, or symptomatic PE, or unsuspected PE in a segmental or more proximal pulmonary artery 
  • Any type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia)

Exclusion Criteria         

  • Less than 18 years old 
  • Life expectancy of less than 6 months 
  • Concomitant thienopyridine therapy or aspirin over 165 mg daily or dual antiplatelet therapy 
  • Active bleeding or high risk of bleeding
  • Recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery 
  • Acute hepatitis, chronic active hepatitis, or liver cirrhosis
  • Uncontrolled hypertension
  • Bacterial endocarditis 
  • Women of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond

This clinical trial is open to adult men and women age 60 and under who are newly diagnosed with FLT3 Mutated Acute Myeloid Leukemia (AML). 

Key Inclusion / Exclusion Criteria:
  • Men and women age between 18 and 60 years old 
  • Newly diagnosed with AML 
  • Detailed eligibility will be reviewed when you contact the study team 

This clinical trial is to evaluate an experimental (investigational) drug in men or women with Nonalcoholic Steatohepatitis (NASH) and liver fibrosis.

Key Inclusion / Exclusion Criteria:

- Men and women who are 18 years of age and older. 
- Treatment naïve individuals with Nonalcoholic Steatohepatitis (NASH) and liver fibrosis. 
- Detailed eligibility reviewed when you contact the study team. 

This clinical trial is for men and women with metastatic colorectal cancer (CRC). Following progression on first-line FOLFOX or XELOX with bevacizumab, patients will be randomized in a 1:1 ratio to BBI-608 plus biweekly FOLFIRI or biweekly FOLFIRI.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Histologically confirmed advanced CRC that is metastatic. 
  • Must have failed treatment with one regimen containing a fluoropyrimidine, oxaliplatin and bevacizumab for metastatic disease. All patients must have received a minimum of 6 weeks of the first-line regimen that included bevacizumab, oxaliplatin and a fluoropyrimidine in the same cycle. Treatment failure is defined as radiologic progression during or < 6 months after the last dose of first-line therapy. 
  • Detailed eligibility reviewed when you contact the study team. 

Video of A Phase III Study of BBI-608 and FOLFIRI in Patients with Metastatic Colorectal Cancer

This behavioral intervention trial is intended for women newly diagnosed with gestational diabetes mellitus (GDM).

Key Inclusion / Exclusion Criteria:
  • Women 18 years of age or older
  • Newly diagnosed with gestational diabetes mellitus between 24-28 weeks of gestation
  • Detailed eligibility reviewed when you contact the study team 

CREST-2 is a study for people who have narrowing of their carotid artery without symptoms caused by that artery like small strokes or temporary strokes. Temporary strokes are often called transient ischemic attacks or TIAs.

Key Inclusion / Exclusion Criteria:

Men and women who:

  • Are 35 years and older 
  • Have narrowing (70% or greater) of at least one of their carotid arteries
  • Lack other serious medical complications

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.